Hikari Power’s Aurinia Pharmaceuticals AUPH Stock Holding History

Hikari Power’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-60,000	Closed	-$440K	–	96
2017 Q1	$440K	Buy	+60,000	New	+$277K	0.06%	56

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Hikari Power's AUPH Position: Q2 2017 in Review

Hikari Power sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2017, closing a stake of 60,000 shares — an estimated $440K sold.

Hikari Power first reported a position in AUPH in Q1 2017 and held it in 1 quarter. The position peaked at $440K in Q1 2017. 65 funds tracked by Wall St. Rank hold AUPH as of Q2 2017.

Hikari Power reported no remaining Aurinia Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Hikari Power sold 60,000 Aurinia Pharmaceuticals shares in Q2 2017, an estimated $440K.
Hikari Power first reported a position in Aurinia Pharmaceuticals in Q1 2017 and held it in 1 quarter.
Hikari Power's Aurinia Pharmaceuticals position peaked at $440K in Q1 2017.
65 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2017.

Based on Hikari Power's 13F filing for Q2 2017, filed 9 Aug 2017.